BioCentury | Oct 30, 2006
Company News

Adventrx, Theragenex deal

...ANX granted Theragenex exclusive U.S. rights to ANX-211 chitosan gel for use in viral-mediated diseases including...
...$1 million milestone on each product based on ANX-211 launched by Theragenex, plus 15-20% royalties. Theragenex...
...Inc. earlier this year (see BioCentury, May 8). Adventrx Pharmaceuticals Inc. (ANX), San Diego, Calif. Theragenex LLC...
BioCentury | Aug 14, 2006
Company News

Secant Pharma LLC, Theragenex deal

...and chronic inflammatory diseases. Further terms were not disclosed. Secant Pharma LLC , Philadelphia, Penn. Theragenex LLC...
BioCentury | Mar 27, 2006
Company News

Ambrilia board of directors update

...Cancer, Infectious Appointed: Bonabes De Rouge, AMB's senior EVP and CSO; Philip Tabbiner, COO at Theragenex...
Items per page:
1 - 3 of 3
BioCentury | Oct 30, 2006
Company News

Adventrx, Theragenex deal

...ANX granted Theragenex exclusive U.S. rights to ANX-211 chitosan gel for use in viral-mediated diseases including...
...$1 million milestone on each product based on ANX-211 launched by Theragenex, plus 15-20% royalties. Theragenex...
...Inc. earlier this year (see BioCentury, May 8). Adventrx Pharmaceuticals Inc. (ANX), San Diego, Calif. Theragenex LLC...
BioCentury | Aug 14, 2006
Company News

Secant Pharma LLC, Theragenex deal

...and chronic inflammatory diseases. Further terms were not disclosed. Secant Pharma LLC , Philadelphia, Penn. Theragenex LLC...
BioCentury | Mar 27, 2006
Company News

Ambrilia board of directors update

...Cancer, Infectious Appointed: Bonabes De Rouge, AMB's senior EVP and CSO; Philip Tabbiner, COO at Theragenex...
Items per page:
1 - 3 of 3